Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Cardiovascular risk reduction with icosapent ethyl
Parth N. Patel
, Siddharth M. Patel
,
Deepak L. Bhatt
Research output
:
Contribution to journal
›
Review article
›
peer-review
23
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cardiovascular risk reduction with icosapent ethyl'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Atherosclerotic Cardiovascular Disease (ASCVD)
100%
Cardiovascular Risk Reduction
100%
Icosapent Ethyl
100%
Ischemic Events
66%
Low-density Lipoprotein Cholesterol Level
66%
Relative Risk Reduction
66%
High Triglycerides
66%
Residual Risk
66%
Triglyceride Reduction
66%
Hazard Ratio
33%
Lipids
33%
Clinical Application
33%
Subgroup Analysis
33%
Randomized Trial
33%
Clinical Benefit
33%
Statins
33%
Triglycerides
33%
Cardiovascular Events
33%
Statin Therapy
33%
Low-density Lipoprotein Cholesterol (LDL-C)
33%
Omega-3 Fatty Acids
33%
Ethyl
33%
Cardiovascular Endpoints
33%
Eicosapentaenoic Acid Ethyl Ester
33%
REDUCE-IT
33%
Independent Risk Factors
33%
Pharmacology, Toxicology and Pharmaceutical Science
Triacylglycerol
100%
Cardiovascular Risk
100%
Icosapentaenoic Acid Ethyl Ester
100%
Low Density Lipoprotein Cholesterol
60%
Coronary Artery Atherosclerosis
60%
Statin (Protein)
40%
Omega-3 Fatty Acid
20%
Lipid
20%